A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease

常染色体显性多囊肾病肾结石治疗综述

阅读:1

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic hereditary disorder and a major cause of end-stage renal disease (ESRD). Urolithiasis is a frequent complication in ADPKD and may contribute to the accelerated decline in renal function. The presence of complex calyceal anatomy, impaired renal function, and associated comorbidities makes stone management particularly challenging in this population. We conducted a narrative review of the literature to explore the underlying reasons for the high incidence of nephrolithiasis in ADPKD, as well as current approaches to management. A targeted literature search was performed in MEDLINE, EMBASE, Google Scholar, and Web of Science for articles published up to February 2025 using the keywords "ADPKD", "nephrolithiasis", "kidney stones," "urolithiasis," "management", and "treatment". Only English-language articles involving human subjects were considered. Original studies, meta-analyses, narrative, and systematic reviews relevant to nephrolithiasis in ADPKD were included. Conference abstracts, editorials, and non-peer-reviewed sources were excluded. Both medical and surgical treatment modalities were evaluated, with attention to reported success rates and complication profiles. Although this is a narrative review and no formal risk of bias assessment was performed, emphasis was placed on including high-quality studies and widely cited literature. Key findings were synthesized thematically to provide an overview of current understanding and management of nephrolithiasis in ADPKD. Small sample sizes and significant heterogeneity in study design, patient selection, and treatment protocols limit available evidence. While the general principles of stone management are similar to those in non-ADPKD patients, therapeutic decisions must be tailored to stone size, location, composition, renal function, and anatomical considerations. Based on the literature, we propose a treatment algorithm to support clinical decision-making. Standardization of management strategies in ADPKD remains an unmet need. Larger, well-designed studies are required to establish evidence-based guidelines for optimal care.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。